Harvoni in Patients With Chronic Hepatitis C Virus (HCV) Infection in Korea

  • End date
    Jan 16, 2022
  • participants needed
  • sponsor
    Gilead Sciences
Updated on 16 August 2021
treatment regimen
chronic hepatitis


The primary objective of this post-marketing surveillance study is to collect and assess data related to the safety and effectiveness of Harvoni (ledipasvir/sofosbuvir (LDV/SOF)) treatment regimen, per the approved Korea prescribing information for Harvoni, in routine clinical practice in Korea and to report the results to the Ministry of Food and Drug Safety (MFDS). Participants will be treated as part of routine practice at Korean healthcare centers by accredited physicians.

Condition Hepatitis C, Hepatitis C virus
Treatment LDV/SOF
Clinical Study IdentifierNCT02951364
SponsorGilead Sciences
Last Modified on16 August 2021


Yes No Not Sure

Inclusion Criteria

Individuals aged 12 years and older who are living in Korea
Adult individuals who have been informed of all pertinent aspects of the study and have voluntarily signed a Personal Information Protection Act (PIPA) consent form; Pediatric individuals who have the individuals' legally authorized representatives sign the PIPA consent form

Exclusion Criteria

Individuals treated with Harvoni outside of the approved prescribing information in Korea
Individuals who have a contra-indication to Harvoni
Individuals who have a contra-indication to ribavirin
Pregnant or breastfeeding women
Individuals who have previously been administered Harvoni
Individuals participating in a concurrent HCV clinical trial
Individuals planning on leaving the country during the study period
Note: Other protocol defined Inclusion/Exclusion criteria may apply
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note